文章摘要

糖尿病性骨质疏松的研究进展

作者: 1黄 燕霞, 1梅 思, 1方 学红, 1,2刘 义
1 广东医科大学广东天然药物研究与开发重点实验室,广东 湛江 524023
2 广东医科大学海洋医药研究院,广东 湛江 524023
通讯: 刘 义 Email: plliu78@sina.com
DOI: 10.3978/j.issn.2095-6959.2020.01.031
基金: 广东省科技技术项目(2017A040405052);广东省促进经济发展专项资金(海洋经济发展用途)(GDME-2018C011);湛江市科技发展专项资金竞争性分配项目(2016A03014);广东医科大学博士启动基金(B2017017)。

摘要

糖尿病性骨质疏松(diabetic osteoporosis,DOP)是糖尿病在人体骨系统中引起的严重慢性并发症,随着糖尿病患者群体的不断扩大,DOP发病率逐年升高,给社会和患者家庭带来巨大的经济负担。DOP发病机制复杂,早期无症状且受目前诊疗方案的限制从而导致患者知晓率低而致残率高。糖尿病患者血糖高、胰岛素样生长因子和胰岛素的缺乏是导致糖尿病性骨质疏松的重要原因,当前对DOP的治疗以降血糖药物联合抗骨质疏松药物为主,控制饮食和加强体育锻炼可以有效预防DOP。
关键词: 糖尿病性骨质疏松;晚期糖基化产物;Wnt/β-catenin通路;诊断;治疗

Research progress of diabetic osteoporosis

Authors: 1HUANG Yanxia, 1MEI Si, 1FANG Xuehong, 1,2LIU Yi
1 Guangdong Key Laboratory for Research and Development of Natural Drugs, Guangdong Medical University, Zhanjiang Guangdong 524023, China
2 Marine Medicine Research Institute, Guangdong Medical University, Zhanjiang Guangdong 524023, China

CorrespondingAuthor:LIU Yi Email: plliu78@sina.com

Foundation: This work was supported by the Science and Technology Project of Guangdong Province (2017A040405052), Special Funds for Economic Development of Marine Economy of Guangdong Province (for Marine Economic Development) (GDME-2018C011)

Abstract

Diabetes-induced osteoporosis (DOP) is a serious chronic complication of diabetes in bone system. The morbidity of DOP is increasing with the continues expansion of diabetic, which caused a huge economic burden to the society. As all known, the pathogenesis of DOP is complicated so that the diagnosis and treatment of disease are limited. The low awareness rate and high disability rate coexist in that the osteoporosis is asymptomatic in the early stage. High blood glucose, insulin-like growth factor, and insulin lack in diabetic patients are meaningful sources of diabetic osteoporosis. The current treatment of DOP depends on hypoglycemic drugs combined with anti-osteoporotic drugs. Controlling diet and enhancing physical exercise could definitely prevent DOP.
Keywords: diabetes-induced osteoporosis; advanced glycation end products; Wnt/β-catenin pathway; diagnosis; treatment